and support biomanufacturing aligned with health , climate , and energy goals . The policy is built on six pillars — skill development , regulatory streamlining , support for biomanufacturing , scaling biotech startups and MSMEs , preferential procurement , and fiscal incentives , emphasizing funding and mentorship for startups , growth facilities for mid-stage ventures , and preferential procurement for local products .
Key goals include creating 300 biotech companies , generating 30,000 jobs , and training 20,000 individuals by 2029 . The policy supports areas like bioagriculture , medical devices , AI / ML in biotech , cell and gene therapies , and space biotechnology with fiscal incentives for startups , MSMEs , and large industries .
Parexel expands real-world research capabilities with new leadership
Parexel is strengthening its Real World Research ( RWR ) capabilities by integrating its Scientific Data Organization ( SDO ) and Real World Evidence ( RWE ) services to meet the growing demand for evidence-based solutions in drug development . The integration aims to optimize research across primary site-based and secondary data / non-site-based studies .
Mike D ’ Ambrosio has been appointed Senior Vice President and Global Head of Real World Research , responsible for enhancing customer engagement and delivering Real World Data ( RWD ) and RWE services . His focus will be on improving patient outcomes and experiences , accelerating drug development timelines , and reducing risks through high-quality RWE .
Before joining Parexel , D ’ Ambrosio led RWE solutions at Syneos Health , driving strategy and delivery across RWE , health economics , and data sciences . Stephen Pyke , Parexel ’ s Chief Clinical Data and Digital Officer , emphasized the importance of RWE in developing complex therapies and highlighted D ’ Ambrosio ’ s leadership as key to driving innovation and strategic collaborations in the healthcare landscape .
BioTech
BIOVOICENEWS . COM 11